Physician profile
Juan Bailey
NPI 1205817624
$18,621.51
in general payments reported to CMS, 2019-2025
14 companies · $1,938 in 2025
The $1,938 reported for 2025 was more than what 85% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $511 · 2020: $300 · 2021: $1,134 · 2022: $1,475 · 2023: $6,579 · 2024: $6,683 · 2025: $1,938.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,180 · Food and Beverage: $5,985 · Travel and Lodging: $1,905 · Education: $130.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,180.00 |
| Food and Beverage | $5,985.18 |
| Travel and Lodging | $1,905.24 |
| Education | $130.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $12,312.89 | 2020-2025 | Biktarvy |
| Viiv Healthcare Company | $4,155.08 | 2019-2025 | Apretude, Dovato, Cabenuva |
| Janssen Biotech, INC. | $744.17 | 2019-2023 | Symtuza |
| Janssen Products, Lp | $623.09 | 2019-2022 | |
| Hologic Sales and Service, LLC | $237.19 | 2023 | Aptima |
| Abbvie INC. | $226.19 | 2019-2023 | Mavyret |
| Astrazeneca Pharmaceuticals Lp | $122.43 | 2024 | Airsupra |
| Janssen Scientific Affairs, LLC | $56.21 | 2021 | |
| Theratechnologies INC. | $46.63 | 2022 | |
| Merck Sharp & Dohme LLC | $34.12 | 2023-2024 | Delstrigo, Pifeltro |
| Janssen Pharmaceuticals, INC | $28.48 | 2021 | |
| Glaxosmithkline, LLC. | $23.32 | 2023 | Trelegy Ellipta |
| Lilly USA, LLC | $11.71 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Juan Bailey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.